†These authors contributed equally.
Academic Editor: Graham Pawelec
Background: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. Methods: We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP. Results: Genetic and immunological markers show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6 (IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing BRAF/MET inhibitors and IL-6 monoclonal antibodies. Conclusions: Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
Craniopharyngiomas (CPs) can result in high levels of morbidity and mortality because of their involvement of critical neurovascular structures. Available treatment strategies, including surgery and radiotherapy, have limitations and known complication profiles. Thus, novel therapies are needed to improve long-term outcomes postoperatively. Currently, no medical therapies are widely established to treat CPs, but recent advances in molecular biology have revealed potential molecular pathways that could be exploited to develop new therapeutics. Targeted molecular therapy has the potential to minimize the adverse outcomes currently associated with medical management of CPs. Here, we performed a scoping review of known molecular pathways and markers identified in the pathogenesis of CP and evaluate studies/case reports and current clinical trials evaluating the use of targeted treatments. Search terms for “targeted treatment”, “craniopharyngioma”, and repeat searches for key identified genes was performed.
CPs are benign epithelial tumors that originate from the sellar region, specifically the craniopharyngeal duct. They are classified as World Health Organization grade I lesions [1] and show a bimodal age distribution, with peak incidence rates observed in children aged 5–14 and adults aged 50–74 years [2]. These tumors are quite rare, with incidences ranging from 0.17 to 0.2 cases per 100,000 people in the U.S [3].
CPs may present with focal neurological deficits, ophthalmologic disturbances, endocrinopathies, and evidence of intracranial hypertension [4, 5]. Ophthalmologic disturbances, seen in 62–84% of patients, may manifest as bitemporal hemianopsia due to compression of the optic chiasm or visual disturbance secondary to intracranial hypertension. Endocrinopathies occur because of damage to the hypothalamic–pituitary axis and can be present at time of diagnosis [6]. Endocrinopathies are seen in 52–87% of patients and include one or more hormonal deficiencies and panhypopituitarism. Patients may also present with diabetes insipidus or develop it along the course of treatment. Focal neurological deficits may include seizures, headaches, nausea, vomiting, and hydrocephalus [7].
Clinical manifestations are heavily dependent on the anatomic location of the CP, specifically whether the tumor is in a prechiasmal, retrochiasmal, or intrasellar location [4]. Tumors in prechiasmal locations are more likely to manifest with visual disturbances and optic atrophy, whereas those in retrochiasmal locations present with increased intracranial pressure and hydrocephalus and intrasellar tumors typically manifest with headache and endocrinopathies. Diagnosis of childhood CP is usually made late, often years after the initial symptoms manifest [8]. In children, any combination of headache, visual deficits, regressed development or reduced growth rate, and/or polydipsia should include CP as a differential diagnosis.
Craniopharyngiomas pose a significant challenge in medical management because of their proximity to neurovascular elements, the hypothalamus, subcortical structures, and the cerebral cortex [9]. An infiltrative and unpredictable growth pattern is often seen, making safe resection difficult. Despite advances in surgical management and radiation, the morbidity and mortality of patients with CP remains high, highlighting a need for the development of novel treatment approaches. CPs have the highest mortality rate of sellar tumors, even after adjusting for other clinical factors [10]. Overall mortality may be 3–5 times higher than the baseline population risk [5, 11]. Morbidity and mortality for CPs are influenced by tumor location, tumor size, and treatment strategy. Overall survival in mixed pediatric and adult populations has been reported to be between 54–96% at 5 years, 40–93% at 10 years, and 66–85% at 20 years, indicating that conventional surgical care is not sufficient for improved survival [5]. Complications of CP treatment can include visual loss, panhypopituitarism, diabetes insipidus, obesity, cardiovascular disease, stroke, sleep disturbances, dysfunctional thermoregulation and thirst, and lower bone density [12].
Current treatment options rely on maximal safe resection; the choice of gross-total resection (GTR) or subtotal resection (STR) depends on the extent of encasement or invasion of critical neurovascular structures. Regardless of the extent of resection, multidisciplinary treatment at experienced centers for management of CPs is favored to improve extent-of-resection and reduce neurological morbidity [13]. Radiotherapy, although beneficial in reducing tumor recurrence, is controversial due to the potential neurovascular morbidity. Post-operative conventional radiotherapy (CRT) for CP is associated with new pituitary deficits, including worsening of partial hypopituitarism, observed in 20–60% of irradiated patients studied in the literature, and radiation induced optic neuropathy [14, 15]. In contrast, fractionated stereotactic radiation therapy (FSRT) and stereotactic radiosurgery (SRS) have lower toxicity rates and greater safety and efficacy in terms of hypothalamic and visual function. As a result, SRS and FSRT have largely replaced CRT methods for post-operative treatment of CP. In addition, optimal timing after tumor resection, whether immediately after surgery or after tumor progression, is undetermined. In a study of adults with CP undergoing GTR, STR + adjuvant radiotherapy, or STR alone, the rates of recurrence were similar between GTR and STR + adjuvant radiotherapy [16]. Furthermore, a meta-analysis of 744 CP patients undergoing GTR vs. STR + adjuvant radiotherapy showed no difference in overall survival and progression-free survival between groups [17]. However, a retrospective review of a pediatric cohort with primary and recurrent CP showed that patients with upfront GTR had significantly longer progression-free survival, supporting the notion that GTR offers a better chance of disease control and cure [18].
On the other hand, several studies have shown that GTR is associated with a higher risk of neurologic, ophthalmic, and endocrinological deficits. In the pediatric population GTR has higher morbidity and mortality related to hypothalamic dysfunction including hyperphagia, hypothalamic obesity, thermal dysregulation, diabetes insipidus, and cognitive deficits [19]. A retrospective, single-center analysis of 178 pediatric patients treated between 1960 and 2017 showed that radical resection was associated with higher risks of worsening visual acuity, panhypopituitarism, diabetes insipidus, psychosocial impairment, and new-onset obesity [20]. Importantly, while conservative management showed a higher risk of multiple recurrences and radiation induced vasculopathy, this was balanced by similar rates of tumor control and a lower risk of long-term morbidities in comparison to GTR. Another retrospective analysis of 30 pediatric patients found that GTR resulted in an average loss of 9.8 points of IQ while a combined surgical/radiotherapy group lost an average of only 1.25 points [21]. Long-term adverse effects of radiotherapy include hormone deficiencies, hearing loss, vision loss, and cognitive worsening [5]. Similarly, a study on the extent of resection and long-term functional outcome in adults with craniopharyngioma found that conservative management led to equal long term visual, endocrinological, and hypothalamic outcomes in comparison to GTR [22]. Additionally, the addition of adjuvant radiotherapy with STR led to better local control of the tumor, and none of the patients that received this intervention had recurrence for more than five years in the follow up period.
Overall, studies have shown that radical resection has similar benefit but an increased risk of deficits compared with STR + adjuvant radiotherapy, which has resulted in a practice shift over time to maximize function and quality of life. These studies remain difficult to compare over time because of variations in treatments strategies. Nonetheless, the refinement of less invasive surgical approaches has helped foster a need to better understand CPs and derive new treatment options.
CPs can occur as either of two primary histologic subtypes, namely adamantinomatous (aCP) and papillary (pCP) (Table 1, Fig. 1). The aCP subtype is more prevalent overall, more common in children and is characterized by cystic and/or solid components, calcifications, necrotic debris, and fibrous tissue [23]. Surgical margins in aCP are more frequently irregular, making resection difficult. Histologic hallmarks include a peripheral basal cell layer of palisading epithelium, loosely aggregated stellate cells, and nodules of wet keratin and anucleated cells [23, 24]. Wet keratin is highly calcified and grossly appears as white flecks.
Characteristic | Adamantinomatous CP | Papillary CP |
Age | More common in children | More common in adults |
Tumor type | Cystic and/or solid components | Solid and/or cystic components |
Calcifications and necrosis debris | Frequent | Uncommon |
Histologic hallmarks | Peripheral basal cell layer of palisading epithelium and nodules of wet keratin and anucleated cells | Squamous epithelium creating papillae of different sizes and lack of a basal cell layer of palisading cells |
Surgical margins | Frequently irregular | Well demarcated |
Invasion | More aggressive | Less aggressive |
Mutation | CTNNB1 | BRAF |
Overview of symptoms and clinical changes from craniopharyngioma.
In contrast, pCPs are more common in adults, are usually well demarcated, and do not tend to invade nearby critical structures. Macroscopically, pCPs are solid or mixed with cystic and solid components. Calcifications are uncommon in pCPs. Histologically, they show growing cells with squamous epithelium creating papillae of different sizes and lack a basal cell layer of palisading cells.
Furthermore, histologic subtyping to determine risk factors for CP recurrence has yielded conflicting evidence. In some studies, pCPs have shown higher 5-year survival rates, less aggressive disease progression, and less risk of recurrence in comparison to aCPs [25]. However, other studies have not found significant differences [6, 26]. Although aCPs are more likely to be invasive and make GTR more challenging, no differences in recurrence have been found between aCPs and pCPs independent of resection status [25]. GTR seems to be the most important factor influencing risk of recurrence.
Not only are their histological features distinct, but aCPs and pCPs demonstrate
differing gene and methylation patterns [27]. DNA methylation profiling after
analysis of the most variably methylated CpG sites has shown that aCPs and pCPs
are characterized by two unique methylation clusters [27]. Therefore, histologic
subtypes also differ on an epigenetic and transcriptional level. Furthermore,
whole-exome sequencing has revealed that aCPs and pCPs consist of mutations that
are mutually exclusive and clonal, specifically catenin beta 1 (CTNNB1)
and B-Raf (BRAF
BRAF mutations are implicated in the tumorigenesis of pCPs. Whole-exome
sequencing, next-generation panel sequencing, pyrosequencing, and Sanger
sequencing revealed the prevalence of BRAF mutations in pCPs in
81–100% of tumors [3, 28, 29, 30]. The BRAF
Recent studies have shown the possibility of targeted therapy with
BRAF
Disruption of the catenin
Signaling pathway and targeting of adamantinomatous
craniopharyngioma. Upregulation of the
Genetically engineered mouse models expressing oncogenic
The
aCPs also show upregulation of SHH signaling (GLI2, PTCH1, and SHH) pathways in
comparison with pCPs. The SHH signaling pathway, essential to organ development
and maintenance of stem cell niches, is also upregulated in both mouse and human
aCPs [24]. SHH binds to the receptor Patched 1 (PTCH1), resulting in
disinhibition of Smoothened (SMO), a transducer. Once active, SMO induces a
signaling cascade and activates target genes. In gene expression studies of aCP
mouse models, SHH was overexpressed in
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that has
also been found to be overexpressed in both human and mouse aCPs [32]. Similarly
to
Different cell populations are implicated in the pathogenesis of aCPs. Cell clusters, characterized by whorl-like patterns near the infiltrative regions of the tumor, have an unknown function but represent a different cell population from other tumor cells [3]. Cell clusters in aCPs have demonstrated differential increased expression of Axin2 and BMP4 RNA as well as increased protein translation in comparison with surrounding tumor cells. In addition, increased cellular migratory potential is seen, indicating that other mechanisms determine which cells form clusters [24, 46].
Sox2+ stem cells represent another distinct population of cells that have been
shown to stimulate tumorigenesis via a paracrine mechanism [3]. Embryonic induced
mice expressing degradation-resistant
The cystic component of CP is responsible for significant symptoms due to mass effect and is associated with a risk of recurrence [56]. Management of cystic CPs may involve intracavitary delivery of radioisotopes or drugs which allows for local treatment to the cyst lining leading to elimination of the secretory epithelial lining and ultimately deficient fluid production and cyst shrinkage [7]. Nonetheless, targeted therapies targeting the cystic component of CPs represent an intriguing potential option for treatment. Several agents have been studied in cystic areas of CP, including P32, interferon (IFN), and bleomycin [57, 58]. However, improved understanding of the cystic components of CP has opened the possibility of more targeted treatment options.
Human aCPs are characterized by a combination of both solid and cystic
components within the tumor, and molecular studies have characterized important
inflammatory mediators in the solid and cystic components. Cystic fluid in human
aCPs has been found to contain elevated levels of cytokines and chemokines,
specifically interleukin (IL)-6, IL-8, IL-10, CXCL1, indoleamine 2, 3-dioxygenase
(IDO)-1, and defensin 1-3 [59, 60]. Similarly, in solid components, transcript
levels of IL-6, CXCL, IL-6, and CXCR2 were elevated. In vitro studies
have identified the role of IL-6 in mitogenesis, growth, and migration of aCP
cells [30, 60]. aCPs were also found to have higher transcript levels of
immunosuppressive factors IL-10 and IDO-1. These findings are relevant given that
they represent the role of immune system modulators in tumor behavior. For
instance, IL-6 is an important activator of the STAT3 pathway, which leads to
chronic inflammation and suppression of antitumor activity when dysregulated
[61]. Similarly, IL-10 has been observed to have an immunosuppressive role in the
brain and in tumor models [62, 63]. Alpha defensins 1–3 and antimicrobial
peptides involved in the innate immune system have been identified in the cystic
component of CPs [59]. Importantly, alpha defensin expression decreases after
treatment of CPs with IFN-
Recurrence of CPs represents a formidable challenge because of the unpredictable behavior, morbidity, and potential mortality. CPs have a recurrence rate of approximately 65%, with most occurring within the first 10 years after surgery [64]. Given that the histologic subtype is not likely to provide prognostic value, other molecular markers may have higher relevance. In terms of histologic features, the presence of cystic lesions or whorl-like arrays in aCPs has been associated with higher risks of recurrence [25]. Reactive gliosis, a response consisting of proliferation and hypertrophy of glial cells after damage, has also been associated with increased rates of recurrence, although only one study has provided supportive evidence [25].
Molecular markers can be significant predictors of CP recurrence. According to Coury et al. [25], molecular markers that have consistently yielded convincing evidence regarding expression and increased risk of recurrence include Ki-67, epithelial cell adhesion molecule (Ep-CAM), pituitary tumor transforming gene (PTTG-1), survivin, specific retinoic acid receptor (RAR) subtypes, osteonectin, and the chemokines CXCL12 and CXCR4. Increased expression of Ki-67, a marker of proliferation in tumors, has been found in aggressive CPs and predicts a higher risk of recurrence and faster tumor growth. Similarly, the antiapoptotic protein survivin is upregulated in the brains of CP patients compared with healthy brains [65]. Interestingly, survivin had higher expression in aCPs compared with pCPs or recurrent tumors. Furthermore, EpCAM, a cell adhesion molecule associated with several cancers, and PTTG-1, an oncogene, show increased expression in recurrent aCPs compared with primary CPs [66]. The presence of osteonectin, a glycoprotein with a role in tumor angiogenesis and proliferation, in the stroma surrounding the CP has also shown a positive correlation with CP recurrence rate [67]. The expression and lack of expression of certain retinoic acid receptor (RAR) subtypes is also associated with recurrence. RARs have a role in cell maturation and differentiation. Low RAR-B and high RAR-y expression in CPs was associated with a higher risk of recurrence within two years of surgery [68]. Finally, expression of chemokines CXCL12/CXCR4 has been associated with worse progression-free survival in pediatric CPs [69].
Moreover, recurrent tumors are characterized by upregulation of angiogenesis, as
driven by vascular endothelial growth factor (VEGF). Indeed, recurrent CPs have
higher expression of VEGF, and aCPs have been shown to have higher VEGF
expression in comparison with pCPs [70, 71]. The latter finding supports previous
descriptions of aCP as more invasive and difficult to resect. More recently,
molecular profiling has revealed the presence of senescent cells in mouse and
human aCPs [72]. Senescent cells secrete senescence associated secretory
phenotype (SASP), proinflammatory cytokines, chemokines, growth factors, and
proteases. SASP is responsible for the recruitment of immune cells for
elimination and promotes the progression of tumor cells via promotion of
angiogenesis, extracellular matrix remodeling, or epithelial mesenchymal
transition. In fact, it has been shown that targeting the SASP response in
Immune checkpoint inhibitors have been used and approved for treatment of a
variety of cancers, and their role in CP management remains to be explored. pCPs
have shown expression of programmed-death ligand 1 (PD-L1) in some tumor cells
[73], and Lin et al. [74] reported that recurrent CPs have more PD-L1–expressing
cells than primary CPs. Another study of PD-L1 expression showed that it was
predominant in the cyst lining of aCP and colocalized with
Various cancers with positive BRAF mutations have been treated with BRAF
inhibitors, including melanomas and thyroid and colorectal cancers [75, 76, 77]. The
identification of BRAF
Paper | Age/Sex | Prior treatment | Targeted treatment agent(s) | Duration | Treatment after targeted therapy | Response to treatment | Final outcome | Complication(s) |
Brastianos et al. 2016 [31] | 39/M | 5 surgeries | dabrafenib 150 mg bid + trametinib 2 mg bid (after 21 days) | 52 days | TSS + RT | 85% and 81% reduction in solid and cystic components at 35 days | stable disease after 18 mo | Low-grade fever |
Aylwin et al. 2016 [32] | 57/F (27 at diagnosis) | 3 surgeries + RT | vemurafenib 960 mg bid | 10 mo (3 mo interruption after 3 mo) | surgery for CSF leak | near-complete resolution after 3 mo | Progression after 7 mo | CSF leak with meningitis due to tumor shrinkage |
Rostami et al. 2017 [29] | 65/M | 1 surgery | dabrafenib 150 mg bid + trametinib 2 mg daily (after 21 days) | 7 weeks | RT | 91% reduction of the tumor at 15 weeks | fever | |
Roque et al. 2017 [33] | 47/F | 1 surgery + Ommaya cyst aspiration + RT | dabrafenib 150 mg bid + trametinib 2 mg daily | 7 mo | none | near disappearance of tumor at 7 mo | intermittent fever | |
Himes et al. 2018 [34] | 52/M (47 at diagnosis) | 1 surgery + RT | dabrafenib 150 mg bid (dose reduction after several weeks then dose was increased to 225 mg daily) | 12 mo | none | significant decrease in tumor size at 6 mo | stable disease 1 year off therapy | joint pain |
Bernstein et al. 2019 [35] | 60/M | 4 surgeries + RT | dabrafenib 150 mg bid + trametinib 2 mg daily (after 14 days) | 28 mo | none | 100% tumor reduction at 2 mo | complete response at 28 mo | verrucal keratosis |
Rao et al. 2019 [36] | 35/M | 1 surgery + shunt | dabrafenib 150 mg bid | 24 mo | none | Complete response of solid component at 24 mo | none | |
Juratli et al. 2019 [37] | 21/M | biopsy | dabrafenib 150 mg bid + trametinib 2 mg daily | 6 mo | none | 80% response at 6 mo | none | |
Khaddour et al. 2020 [38] | 39/M | 1 surgery | dabrafenib 150 mg bid + trametinib 2 mg daily | 9 mo | gamma knife radiosurgery | in remission for 2 years | mild fever | |
Di Stefano et al. 2020 [39] | 55/F | 1 surgery | dabrafenib 150 mg bid + trametinib 2 mg daily | 12 mo | RT | 94.5% tumor shrinkage after 72 days | stable at 385 days | fatigue, coughing, peripheral edema |
Chik et al. 2021 [40] | 37/M (10 at diagnosis) | 4 surgeries | vemurafenib 960 mg bid | 40 mo | 2 surgeries followed by RT and gamma knife | 55% tumor reduction at 15 mo | arthralgia, myalgia, elevated liver enzymes, severe sun sensitivity | |
RT, radiotherapy; bid, twice daily; TSS, transsphenoidal surgery; CSF, cerebrospinal fluid. |
Signaling pathway and targeting of papillary craniopharyngioma.
Constitutive activation of the BRAF signaling pathway occurs with the V600E
mutation in papillary craniopharyngioma. Inhibition of BRAF
Single-agent therapy with the BRAF inhibitor dabrafenib (150 mg by mouth twice daily) or vemurafenib (960 mg by mouth twice daily) was used in 4 cases [32, 34, 36, 40]. Dual targeted therapy using trametinib (2 mg by mouth daily), in combination with BRAF inhibitor, was prescribed in 7 patients [29, 31, 33, 35, 37, 38, 39]. Regardless of treatment regimen, all case reports demonstrated favorable clinical response. Tumor volume reduction—ranging from 55% to 100%—was seen in all cases, and both solid and cystic portions of tumor were responsive to treatment. These reports mostly included patients with progressive or recurrent pCP that had failed primary treatment. The interruption of treatment because of side effects resulted in tumor regrowth in 2 cases; however, the tumors shrank again after readministration of agents in both cases [29, 32, 33, 34, 35, 36, 37, 38, 39, 40]. In another case, Himes et al. [34] reported stable disease over 1 year after discontinuation of dabrafenib therapy.
Combined BRAF and MEK inhibitors have been well tolerated in all reported
patients. One patient with recurrent BRAF
Preoperative treatment with BRAF/MEK inhibitors may be helpful as a neoadjuvant
treatment by reducing tumor volume. Juratli et al. [37] reported a
patient with BRAF
Recently, minimally invasive and noninvasive methods for preoperative tumor
diagnosis including the use of magnetic resonance imaging characteristics that
predict BRAF-mutated pCP [41, 85] and detection of circulating
BRAF
EGFR inhibitors, as either monoclonal antibodies or tyrosine kinase inhibitors, represent a potential therapeutic in the management of CPs and have been efficacious for the treatment of non–small-cell lung cancer (NSLC), breast, and colorectal cancer [86]. Indeed, in vitro experiments have demonstrated that gefitinib (a selective EGFR inhibitor) treatment prevents migration and motility of tumor cells and significantly reduces fascin mRNA expression in aCP cells [78]. In addition, EGFR inhibitors could provide another therapeutic benefit by increasing tumor cell sensitivity to radiation [53]. Further animal models and preclinical studies will be needed to investigate the benefit of EGFR inhibitors in the treatment of aCPs.
VEGF regulates angiogenesis and promotes tumor growth, metastasis, and
recurrence [86, 87]. One downstream pathway in aCP of Wnt/
The role of the immune microenvironment in CP pathogenesis is increasingly
recognized in recent years [94], and several studies have attempted to evaluate
the use of selective inflammatory blockade as a potential therapeutic target for
treatment of aCP [44]. IFN has antitumor activity through inhibition of cell
proliferation and modulation of the host’s immune response [95, 96]. Several
studies have investigated the efficacy of intracystic and systemic administration
of IFN with promising results. Cystic treatment can delay surgery or radiotherapy
through cyst shrinkage, which can reduce the patient’s risk profile for
treatment, especially in children [97, 98, 99, 100]. Jakacki et al. [101] reported the result of
systemic IFN-
Targeting of IL-6 has been evaluated as a method to modulate inflammatory signaling in CPs. Grob et al. [93] reported the first systemic use of tocilizumab, a monoclonal antibody against IL6-R, in the management of two patients with cystic aCP that was refractory to intracystic therapy. They administered tocilizumab alone in one patient and tocilizumab in combination with bevacizumab (VEGF inhibitor) in another. A partial tumor response and significant decrease in cyst volume were seen in both patients. Grob et al. [93] proposed tocilizumab as a new potential agent for the treatment of cystic aCP. Currently, a Phase 0 clinical trial (NCT03970226) is investigating the efficacy of tocilizumab in the management of aCP.
Only a handful of clinical trials are currently evaluating targeted agents in CP
(Table 3). A Phase 2 clinical trial (NCT03224767) is investigating the combined
use of BRAF and MEK inhibitors (vemurafenib and cobimetinib) for the treatment of
BRAF
Clinical trial | Phase | Molecular target | Objective |
NCT03224767 | II | BRAF Pathway | To study the combined used of BRAF and MEK inhibitors (vemurafenib and cobimetinib) for the treatment of BRAF |
NCT03970226 | Zero | IL-6 | To study the role of tocilizumab, a monoclonal IL-6 antibody, in treatment of newly diagnosed/progressed aCp in children and adolescents ages 2–21 years |
NCT03610906 | I/II | To identify new potential areas of target in pediatric patients |
NCT03970226 is a phase 0 study examining the role of tocilizumab, a monoclonal IL-6 antibody, in the treatment of newly diagnosed and progressed aCPs in children and adolescents 2 to 21 years of age. In this study, patients are given systemic tocilizumab, and the presence of drug metabolites, IL-6 levels, and other inflammatory markers are measured within tumor tissue, tumor cyst, or CSF fluid. If drug metabolites are detected, patients are eligible for concurrent enrollment to evaluate the efficacy of tocilizumab by measuring progression-free survival, overall response rate, 1-year disease stabilization, and tissue analysis using various biomarkers. Lastly, NCT03610906 is a phase 1/2 study that aims to identify new potential areas of target in pediatric patients but is not examining any targeted treatment.
There are multiple promising genetic and molecular biomarkers being explored for prognostic and therapeutic purposes in CP. Differences in histology, namely between aCP and pCP, do not necessarily correlate with prognosis and outcomes; however, different mechanisms for pathogenesis of these subtypes have aided in understanding the disease and targeting therapeutics. Overexpressed oncogenes in CP include genes controlling cell growth, proliferation, and angiogenesis among other pathways. These mutations can serve as both therapeutic targets and biomarkers of prognosis. Furthermore, variations in molecular markers can be seen in recurrent versus primary CP, indicating that differences in mutational signatures could potentially help understand and predict recurrence. Inhibition of some genes overexpressed in recurrent CP may be able to reduce recurrence rates overall. Currently, the primary treatment for recurrent CPs should include repeat surgery or radiosurgery given that current investigative targeted therapies are emerging.
Oncogenic gene mutations in CP are also implicated in other forms of cancer and have been targeted for therapy with molecular inhibitors. Drugs targeting these pathways have been tested with reasonable success on medically managed CPs. Apart from pure medical treatment, a promising application for such drugs is for neoadjuvant therapy to be followed by radiation or resection. EGFR inhibitors could both prevent tumor growth and sensitize the tumor to subsequent radiation therapy. Inhibitors of the BRAF/MEK pathway in pCP have proven to be effective in shrinking tumors and may facilitate resection. VEGF inhibitors, in combination with IL-6 inhibitors, have also been shown to reduce tumor size, although no studies have been done with VEGF inhibitors alone. Further studies and clinical trials are needed to examine these applications for their therapeutic potential. Immunotherapy may also have potential for combating CP growth and spread. Current clinical trials are examining the use of IL-6 inhibition in CP treatment. The expression by pCP tumors of PD-L1, especially in recurrent tumors, also suggests anti-PD-1/PD-L1 immunotherapy as a potential route for CP therapy.
Challenges remain in applying our knowledge of molecular drivers towards clinical treatment in CP. Only a handful of clinical trials are currently evaluating the role of molecular treatments, with reports of successful agents only being found in rare case reports. Driver mutations and their associated signaling pathways should be further explored within in vitro and animal models; however, clinical studies are also required to translate the therapeutic value in CP management and establish the efficacy of these agents.
MR, MT, SY, AS, SC, and GNP researched and wrote the paper. JJE and MK edited the paper. All authors contributed to editorial changes in the paper. All authors read and approved the final paper.
Not applicable.
We thank Kristin Kraus for her editorial assistance. Biorender.com was used for the drafting of Figs. 2,3 in this paper.
This research received no external funding.
The authors declare no conflict of interest. JJE (Mizuho–royalties), MK (Thieme–royalties).